The EOC202 overseas trial significantly improved the total survival of patients with advanced breast cancer

Recently, Immutep, an overseas partner of EFTilagimod alpha, which is developing eFTilagimod alpha, officially announced the results of its clinical IIb phase trial (AIPAC) in Europe, encouraging data.
this is the first time in the world that LAG3 fusion proteins, acting as antigen-delivered cell (APC) agonists, have been observed to benefit the total lifetime (OS) of metastasis breast cancer patients in randomized double-blind, placebo-controlled trials.
results showed clear trends in OS improvement in the total patient population: median OS was 2.7 months longer than in the combined chemotherapy control group, while significant and statistically different OS benefits were observed in pre-defined patient populations: in patients under 65 years of age, median OS was extended by 7.1 months, nearly 50 percent higher than in the control group (21.9 months vs. vs. 14.8 months); In patients with low monocyte counts, the medium OS was extended by 9.4 months, up 74% from the control group (22.4 months vs. 12.9 months).
same time, immutep's ongoing Global Phase II Clinical Trial (TACTI-002) of the eftilagimod alpha joint PD-1 inhibitor Keytruda has recently obtained instructive interim results. The total remission rate (ORR) was .4%, of which 2 patients achieved complete remission (CR), and in the second-line treatment group of head and neck squamous cancer (HNSCC), ORR reached 44% (more than triple the ORR of about 15% in the KEYNOTE study), of which 3 patients reached CR.
more importantly, the therapy showed very encouraging data in patients with low PD-L1 expression, who were generally insensitive to immunosupergery (PD-L1) inhibitor therapy.
based on these results, Immutep decided to expand the NSCLC first-line treatment group to 74 patients from the end of 2020, and to communicate with the drug regulatory agency on the next phase of clinical research strategies for HNSCC.
the above overseas research results have laid a favorable foundation for EOC202's active promotion in China.
Tengjing Ang Pharmaceuticals is about to launch a randomized double-blind, placebo-controlled clinical Phase II trial of EOC202 to treat metastasis breast cancer in China.
, similar to AIPAC, clinical studies in China will continue to focus on HER2-negative/HR-positive metastatic breast cancer patients who are suitable for chemotherapy after progression in endocrine therapy, while refining the treatment population to maximize potential research benefits.
the trial is expected to be conducted in 20 research centers in China in a group of about 152 patients, and is expected to achieve the first patient dosing in the first quarter of 2021.
Prior to this, ETEN Jingang Pharmaceuticals had completed the clinical Phase I bridging trial of EOC202 in China, which included 12 patients, proving that EOC202 was safe in the Chinese patient population, and that there was no significant racial difference between the pharmacodynamic characteristics and the European population.
addition, Etenjing Ang Pharmaceuticals is actively discussing with Immutep a follow-up clinical trial of the eftilagimod alpha in collaboration with Keytruda for the treatment of NSCLC and HNSCC.
"The combined treatment of EOC202 shows consistent and good safety in The Chinese patient population, consistent with overseas trial data," said Professor Hu Xichun, Director of Oncology At Fudan University Affiliated Oncology Hospital in Shanghai and lead researcher of the EOC202 China clinical trial.
results of AIPAC are very encouraging, and the observed OS extension echoes significant and sustained growth of T-cells in patients in the treatment group, which also validates the mechanism by which EOC202 acts as an immune activator for activating APC.
we look forward to the next Clinical Phase II trials.
is the most common malignant tumor among Chinese women at present, " said Dr. Z. Xiaoming, CEO of YiTeng Jingang Pharmaceuticals, a pharmaceutical company in China.
2015 China's cancer statistics show that more than 270,000 new cases of breast cancer, more than 70,000 deaths.
is still the standard treatment for HER2-negative/HR-positive metastasis breast cancer patients, it is important to find new ways to enhance the efficacy of yew alcohol chemotherapy.
encouraging AIPAC interim results recently published by Immutep, we see hope that patients will benefit by activating the body's immune system.
, chief executive of Immutep, said: "Etonian, like us, is delighted to see the huge potential of eftilagimod alpha in a joint treatment for metastatic breast cancer with yew alcohol.
AIPAC trials fully assessed the effectiveness of this combination therapy and convinced us that eftilagimod alpha would significantly benefit patients with metastasis breast cancer.
Phase II trial in China will accelerate the entry of this innovative therapy into the Chinese market for the benefit of a wide range of patients.
" References: M G Krebs, M Majem, E Felipe, et al. A Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung (NSCLC) or head and neck carcinoma (HNSCC). SITC 2020 Poster (Abstract ID: 790)[2] Seiwert T Y et al, 2016; Lancet 17: 956-965 (KN-012)[3]Cohen E, et al. Lancet 2019; 393: 156-167 (KN-040)[4] Wanqing Chen, Rongshou Zheng, Peter D.B, et al. Cancer Statistics in China. CA CANCER J CLIN 2016; 66: 115-132。